Remove Cardiology Remove Containment Remove Drugs
article thumbnail

Are Statin Side Effects ‘All in Your Head’?

The Pharma Data

But after giving the patients an unmarked eight-month supply of statins and dummy pills (four bottles of each), the investigators found that 90% of the symptoms reported when taking the real drug endured, even when patients were taking a dummy (placebo) pill. The study received no drug industry funding.

article thumbnail

Sequana Medical Appoints Two Additional Experts as Heart Failure Scientific Advisors

The Pharma Data

Michael Felker, MD, MHS, FACC, FAHA, FHFSA is Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine. He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology. About Dr. Udelson James E.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development

The Pharma Data

It plays a crucial role in many inflammatory and autoimmune diseases across multiple therapy areas, including haematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. 5% have US Food and Drug Administration -approved treatments. The complement cascade is pivotal to the innate immune system.

article thumbnail

FDA Grants 510(k) Clearance for Abiomed’s Innovative Cardiopulmonary Support Technology

The Pharma Data

–( BUSINESS WIRE )– The United States Food and Drug Administration (FDA) has granted Abiomed (NASDAQ: ABMD) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System. Food and Drug Administration (FDA) to provide extracorporeal circulation. 26, 2020 11:55 UTC.

article thumbnail

Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference

The Pharma Data

The Clinical Trial Approval (CTA) scheme for ALXN1820 (bi-specific anti-properdin mini-body) and the Investigational New Drug (IND) application for ALXN1850 (next generation asfotase alfa) have been accepted, in Australia and the U.S. respectively, with Phase 1 studies expected to begin in the first half of 2021. Forward Looking Statements.

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. However, these drugs have shown limited effectiveness in treating HFpEF. Case Study: Genomic Approaches in Coronary Artery Disease Drug Development.

article thumbnail

Alexion Reports Third Quarter 2020 Results

The Pharma Data

Pending collection of 12-month safety and drug-device combination data, Alexion plans to file for approval in the U.S. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care.

Sales 40